Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Supported in part ...

First-line treatment for metastatic melanoma continues to focus on immunotherapy. Long-term data from the CheckMate 067 trial confirmed the superiority of nivolumab combined with ipilimumab ...

This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma. It is for people whose melanoma has grown ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Immune checkpoint inhibitors used for melanoma include: Pembrolizumab (Keytruda) and nivolumab (Opdivo) — These block the protein PD-1, taking the brakes off your T cells and allowing these immune ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

More information: Huang R et al, Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...